{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:10:12Z","timestamp":1762114212382,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008387","name":"Xi'an Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cca.2025.120487","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:11:13Z","timestamp":1752567073000},"page":"120487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Analysis of factors affecting laboratory alert level of trazodone based on therapeutic drug monitoring data"],"prefix":"10.1016","volume":"577","author":[{"given":"Jing","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suo","family":"zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120487_b0005","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2025.120487_b0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.cca.2025.120487_b0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.2018.87","article-title":"Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort","volume":"213","author":"Fond","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.cca.2025.120487_b0020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/15622975.2017.1379609","article-title":"Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement","volume":"19","author":"Dodd","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.cca.2025.120487_b0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cca.2025.120487_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222855","article-title":"Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and a1-adrenoceptor antagonism","volume":"14","author":"Montalbano","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2025.120487_b0035","unstructured":"Sleep Medicine professional committee of the cross-strait association for medicine. Chinese expert consensus on clinical application of trazodone. Natl. Med. J. China 102 (2022) 468\u2013478."},{"key":"10.1016\/j.cca.2025.120487_b0040","first-page":"572","article-title":"Trazodone is metabolized tomchlorophenylpiperazine by CYP3A4 from human sources","volume":"26","author":"Rotzinger","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cca.2025.120487_b0045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00007691-200208000-00016","article-title":"Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients","volume":"24","author":"Mihara","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2025.120487_b0050","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1124\/dmd.107.019471","article-title":"Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine","volume":"36","author":"Wen","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cca.2025.120487_b0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00325481.2017.1249265","article-title":"A review of trazodone use in psychiatric and medical conditions","volume":"129","author":"Khouzam","year":"2017","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.cca.2025.120487_b0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/FTD.0000000000001178","article-title":"Analysis of factors affecting concentrations and concentration-to-dose ratios of trazodone","volume":"46","author":"Song","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2025.120487_b0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.forsciint.2015.04.009","article-title":"Postmortem distribution of trazodone concentrations","volume":"251","author":"McIntyre","year":"2015","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.cca.2025.120487_b0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/15563650701275322","article-title":"QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone","volume":"46","author":"J.A. Service, W.S. Waring","year":"2008","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.cca.2025.120487_b0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004850-199510030-00002","article-title":"Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine","volume":"10","author":"Ishida","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cca.2025.120487_b0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/FTD.0000000000000921","volume":"44","author":"Ding","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2025.120487_b0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000368559","article-title":"Efficacy and safety of prolonged\u2011release trazodone in major depressive disorder: a multicenter, randomized, double\u2011blind, flexible\u2011dose trial","volume":"94","author":"Zhang","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.cca.2025.120487_b0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/YIC.0000000000000304","article-title":"A randomized, double\u2011blind study comparing the efficacy and safety of trazodone once\u2011a\u2011day and venlafaxine extended\u2011release for the treatment of patients with major depressive disorder","volume":"35","author":"Fagiolini","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cca.2025.120487_b0095","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1185\/030079906X121039","article-title":"A comparative, randomized, double\u2011blind study of trazodone prolonged\u2011release and sertraline in the treatment of major depressive disorder","volume":"22","author":"Munizza","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.cca.2025.120487_b0100","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1185\/030079905X53243","article-title":"A comparative, randomised, double\u2011blind study of trazodone prolonged\u2011release and paroxetine in the treatment of patients with major depressive disorder","volume":"21","author":"Kasper","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.cca.2025.120487_b0105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2021.1195","article-title":"Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US","volume":"325","author":"Maust","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2025.120487_b0110","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40266-016-0380-3","article-title":"Changing pattern of sedative use in older adults: a population-based cohort study","volume":"33","author":"Iaboni","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.cca.2025.120487_b0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-0327(96)00089-4","article-title":"Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression","volume":"41","author":"Maes","year":"1996","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cca.2025.120487_b0120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/JCP.0b013e31822bb1d9","article-title":"A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult chinese patients with treatment\u2011resistant major depression","volume":"31","author":"Fang","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cca.2025.120487_b0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phrs.2004.06.007","article-title":"Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study","volume":"51","author":"Bertschy","year":"2005","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cca.2025.120487_b0130","first-page":"572","article-title":"Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources","volume":"26","author":"Rotzinger","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cca.2025.120487_b0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003088-199834040-00002","article-title":"Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications","volume":"34","author":"Caccia","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cca.2025.120487_b0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000319744","article-title":"Antidepressants: clinically relevant drug interactions to be considered","volume":"86","author":"Schellander","year":"2010","journal-title":"Pharmacology"},{"key":"10.1016\/j.cca.2025.120487_b0145","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/FTD.0000000000001049","article-title":"Influence of genetic polymorphisms on the pharmacokinetics of trazodone hydrochloride: a scoping review and future perspective","volume":"45","author":"Meulman","year":"2023","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.cca.2025.120487_b0150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5414\/CPP42120","article-title":"Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine?","volume":"42","author":"Prapotnik","year":"2004","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125003663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125003663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:07:14Z","timestamp":1762114034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125003663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S0009898125003663"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120487","relation":{},"ISSN":["0009-8981"],"issn-type":[{"type":"print","value":"0009-8981"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of factors affecting laboratory alert level of trazodone based on therapeutic drug monitoring data","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120487"}}